Case Studies
Closed deals, in detail.
How we defended value, managed the human side, and structured outcomes that met owners’ goals, start to close.
Closed engagements
Strategic Bolt-On & Succession Exit · 2024
Defending Value in Bio-Pharma Engineering
9.0× EBITDA defended · +20–25% EBITDA uncovered Read case study →
Majority Recapitalization · 2025
Orchestrating a Sophisticated Founder Transition
2.0× above 2025 benchmark · all-cash close Read case study →
Sell-Side Platform Sale
Turning a Retention Discount into a Premium Outcome
3× ARR · 12× EBITDA · all-cash, team retained Read case study →
Corporate Carve-Out & Cross-Border Sale · 2023
Carving Out a Non-Core Division
Going concern preserved · cross-border strategic buyer Read case study →Your Deal, Next
Every case study started with a conversation.
Talk to the principal who would run your process.